Biomarkører ved diagnostik af Alzheimers sygdom i tidlig fase

Translated title of the contribution: Biomarkers for early diagnosis of Alzheimer's disease

Abstract

Alzheimer's disease is responsible for 40-50% of dementia cases. Future treatment may include disease-modifying compounds unlikely to be efficient if administered late in the course, thus necessitating early diagnosis. Furthermore, revised diagnostic research criteria that include biomarkers of pathological accumulation of cortical beta-amyloid (decreased beta-amyloid in cerebrospinal fluid and amyloid imaging) and neurodegeneration (structural MRI and 18F-FDG-PET), have been published. Future research is needed to determine specific evidence-based application of these biomarkers in the clinic as well as discovery of novel biomarkers.

Translated title of the contributionBiomarkers for early diagnosis of Alzheimer's disease
Original languageDanish
Article numberV12140684
JournalUgeskrift for Laeger
Volume177
Issue number24
ISSN0041-5782
Publication statusPublished - 8 Jun 2015

Fingerprint

Dive into the research topics of 'Biomarkers for early diagnosis of Alzheimer's disease'. Together they form a unique fingerprint.

Cite this